Ashley Gallagher, MA

Every pattern of hormonal contraceptive use was associated with subsequent semaglutide initiation, a signal pharmacists and prescribers should watch for.

New survey data reveal information gaps in respiratory syncytial virus immunization decisions.

Voluntary licensing agreements covering 129 low- and middle-income countries arrive as phase 3 trials continue.

Large trial emulation study finds a 21% reduction in 3-year fracture risk compared with DPP-4 inhibitors, independent of weight loss or glycemic changes.

As extreme heat becomes more frequent, common prescription and OTC medications can raise a patient's risk of heat illness and sunburn.

Newly filed charters arrive as pharmacy groups already press HHS over similar changes to the CDC's vaccine advisory panel.

Viatris' new transdermal patch adds a low-dose estrogen option to the contraceptive landscape.

A study found antibody deficiencies and monoclonal immunoglobulins in a share of adults hospitalized with invasive pneumococcal disease.

A 4-year cohort study finds pneumococcal vaccine serotypes circulating and increasing among older adults with community-acquired pneumonia.

The opioid-free product pairs acetaminophen with naproxen in a single dose, giving pharmacists a new counseling point for patients.

The approval is backed by pivotal phase 3 trials and carries boxed warnings for suicidal ideation in pediatric patients and abuse potential.

Positive results from TRIUMPH-2 and TRIUMPH-3 bring retatrutide's obesity program to 5 successful trials, with Lilly planning to submit in early 2027.

The autoinjector cuts administration to under 10 seconds, offering patients an at-home option for fluid overload in heart failure and chronic kidney disease.

A new survey shows widespread uncertainty about which vaccines the CDC recommends during pregnancy, underscoring the counseling role pharmacists play.

New policies urge pharmacists to identify disinformation and seek legal protection against AI-generated impersonation.

Detailed results show the investigational islatravir/lenacapavir combination sustained virologic suppression as a potential once weekly HIV treatment.

Pharmacists and other clinicians counseling postpartum patients may find more success with meal-timing strategies that require minimal disruption to routines.

A new report on glucagon-like peptide-1 receptor agonists for obesity finds real clinical value alongside budget impact that already exceeds the review's own threshold.

Vaccine guidance in the US is undergoing a dramatic change, leaving pharmacists uncertain about coverage, authority, and flu-season timing.

A secret shopper study finds most are still compounding semaglutide and tirzepatide with additives, often through suppliers lacking sterile compounding licenses.

Bivalent mRNA and protein-based fourth doses produce comparable protection against Omicron JN.1 infection over 12 months.

Pharmacist credentialing unlocks payer contracts and boosts reimbursement and can help avoid risky third-party billing as clinical services expand.

A rapidly growing multistate cyclosporiasis outbreak has pushed national case counts to nearly 7000.

Nine pharmacy organizations state that the revised charter overemphasizes vaccine risk and could delay recommendations pharmacists rely on for scope of practice and insurance coverage.

Lipfendra (enlicitide) showed placebo-adjusted low-density lipoprotein cholesterol reductions of more than 50% in 2 phase 3 trials.

Emerging data show glucagon-like peptide-1 receptor agonists may raise the risk of certain autoimmune diseases compared with other diabetes drugs.

Investigators test 3 repurposed drugs alongside specialist care, finding small, transient fatigue improvements for long COVID fatigue.

New research links a national surge in poison control calls involving semaglutide to preventable dosing mistakes rather than intentional misuse.

Subcutaneous lecanemab-irmb can now be self-administered or given by a caregiver from the first dose, eliminating the requirement for an initial in-clinic intravenous infusion.

A new analysis shows that socioeconomic status shrinks type 2 diabetes risk far more for nonHispanic white and Asian Americans than for nonHispanic Black and Hispanic Americans.